IJCRR - 6(9), May, 2014
Pages: 145-155
CURRENT TREATMENT PARADIGMS FOR RETINOBLASTOMA
Author: Shanti Pandey, Kavita Pandey, Vijay Joshi, Swati Gupta, Kalpana
Category: Healthcare
[Download PDF]
Abstract:
Retinoblastoma is a primary malignant neoplasm of the retina that arises from immature retinal cells
which affects infants and children and it is the most common primary tumor of the eye in children.
Retinoblastoma detected on time can lead the child to see and moreover can save his life.
Retinoblastoma in later stages can endanger life. It becomes essential to know most about this life
threating as well as sight threating condition. Let these children live and enjoy the color of life.
Keywords: Retinoblastoma, chemotherapy, tumor, eye
Citation:
Shanti Pandey, Kavita Pandey, Vijay Joshi, Swati Gupta, Kalpana. CURRENT TREATMENT PARADIGMS FOR RETINOBLASTOMA International Journal of Current Research and Review. 6(9), May, 145-155
References:
REFERENCES
1. Donaldson SS, Egbert PR, Lee W. In: Pizzo PA, PoplackDG(eds). Principles and Practice of Pediatric Oncology.JBLippincott: Philadelphia, 1993, pp 683–696.
2. SheildsJA,Sheilds CL. Management and prognosis of retinoblastoma.In intraocular tumors. A text and atlas Philadelphia:WB Saunders 1992;337-392.
3. KnudsonAG:Mutation and cancer:Statistical study of retinoblastoma.ProcNatlAcadSci,USA 1971:68:820-823.
4. Kingston JE, Hungerford JL, Madreparla SA, Plowman PN. Results of combined radiotherapy and chemotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996;114:1339-1343.
5. Shields CL, Honavar SG, Shields JA, Dimirci H, Medows AT, Naduvilath TJ. Factors predictive of recurrence of retinal tumors ,vitreous seed, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002;120:460-464.
6. Shields CL, MashayekhiA ,Shelids JA, Cater J, Medows AT, Shields JA. Chemoreduction for retinoblastoma. Analysis of tumour control and risk of recurrence in 457 tumors.AM J Ophthalmol 2004;138:329-37.
7. Shields CL, MashayekhiA ,Shelil A, Ness S, Cater J, Medows AT, Shields JA.Macularretinoblastoma managed with chemoreduction. Analysis of tumor control with without thermotherapy in 68 tumors, Arch Ophthalmol 2005;123:765-73.
8. Honavar SG, Singh AD, Shields CL ,Medows AM, Dimirci H, Cater J, Shields JA . Postenucleation adjuvant therapy in high -risk retinoblastoma, Arch Ophthalmol 2002;120:923-931.
9. Ellsworth RM. The practical management of retinoblastoma. Trans Am OphthalmolSoc 1969:67:462-534.
10. Chantada G, Doz F, Antoneli CB ,et al A proposal for an international retinoblastoma staging system Pediatr Blood Cancer 2006:47;801-805.
11. Gombos D.S., Kelly A., Coen P.G., et al: Retinoblastoma treated with primary chemotherapy alone: the significance of tumor size, location, and age. Br J Ophthalmol 2002; 86:80-83.
12. Gallie BL, Budning A, Deboer G, Thiessen JJ, Koren G, Verjee Z, etal. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophtalmol 1996;114:1321-8.
13. Shields CL, De Potter P, Himelstein BP ,Shields JA , Medows AT, Maris JM. Chemoreduction in the initial management of intraocular retinoblastoma.ArchOphthalmol 1996;114:1330-8.
14. Murthy R, Honavar SG, Naik MN, Reddy VA. Retinoblastoma. In: Dutta LC, ed. Modern Ophthalmology. New Delhi, India ,Jaypee Brothers;2004:849-859.
15. Chan H.S., DeBoer G., Thiessen J.J., et al: Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res. 1996; 2:1499-1508.
16. Heidemann RL, Cole DE, Balis F et al. Phase I and pharmacoqkinetic evaluation of thiotepa in the cerebrospinal fluid andplasma of pediatric patients: evidence for dosedependent plasma clearance of thiotepa. Cancer Res 1989; 49: 736–741.
17. B Kremens, R Wieland, H Reinhard, D Neubert, JD Beck, T Klingebiel, N Bornfeldand W Havers.High-dose chemotherapy with autologous stem cell rescue in childrenwith retinoblastoma. Bone Marrow Transplantation (2003);31: 281–284.
18. Shields C.L., Mashayekhi A., Cater J., et al: Chemoreduction forretinlblastoma: analysis of tumor control and risks for recurrence in 457 tumors. Trans Am Ophthalmol Soc. 2004; 102:35-44.
19. Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Singh A, Friedman DL, Naduvilath TJ. Chemoreduction plus focal therapy for retinoblastoma:factors predictive of need for treatment with external beam radiotherapy or enucleation. AmJ Ophthalmol.2002;133:657-64.
20. Matsubara H, Makimoto A, Higa T, Kawamoto H, Sakiyama S, Hosono A, Takayama J, Takaue Y, Murayama S, Sumi M, Kaneko A, Ohira M. A multidisciplinary treatment strategy thatincludes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement.Bone Marrow Transplant. 2005 Apr;35(8):763-6.
21. Dunkel IJ, Khakoo Y, Kernan NA, Gershon T, Gilheeney S, Lyden DC, Wolden SL, Orjuela M, Gardner SL, Abramson DH. Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma Pediatr Blood Cancer. 2010 Jul 15;55(1):55-9.
22. Dunkel IJ, Chan HS, Jubran R, Chantada GL, Goldman S, Chintagumpala M, Khakoo Y, Abramson DH. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma.Pediatr Blood Cancer. 2010 Jul 15;55(1):149-52.
23. Dunkel IJ, Jubran RF, Gururangan S, Chantada GL, Finlay JL, Goldman S, Khakoo Y, O'Brien JM, Orjuela M, Rodriguez-Galindo C, Souweidane MM, Abramson DH. Trilateralretinoblastoma: potentially curable with intensive chemotherapy. Pediatr Blood Cancer. 2010 Mar;54(3):384-7.
24. Honavar SG, Shome D, Reddy VAP. Periocular carboplatin in the management of advanced intraocular retinoblastoma. Proceedings of the XII International congress of ocular Oncology,Vancouver,Canada,2005.
25. Honavar SG, Singh AD. Management of advanced retinoblastoma.OphthalmolClin North Am.2005;18:65-73.
26. Khelfaoui F., Validire P., Auperin A., et al: Histopathologic risk factors in retinoblastoma. A retrospective study of 172 patients treated in a single institution. Cancer 1996; 77:1206-1213.
27. Brooks H.L., Meyer D., Shields J.A., et al: Removal of radiation-induced cataracts in patients treated for retinoblastoma. Arch Ophthalmol 1990; 108:1701-1708.
28. Egbert P.R., Donaldson S.S., Moazed K., et al: Visual results and ocular complications following radiotherapy for retinoblastoma. Arch Ophthalmol 1978; 96:1826-1830.
29. Roarty J.D., McLean I.W., Zimmerman L.E.: Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 1988; 95:1583-1587.
30. Mohney B.G., Robertson D.M., Schomberg P.J., Hodge D.O.: Second nonocular tumors in survivors of heritable retinoblastomaand prior radiation therapy. Am J Ophthalmol 1998; 126:269-277.
31. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma; a possible age effect on radiation-related risk. Ophthalmology.1998;105: 573-580.
32. Shields C.L., Shields J.A., De Potter P., et al: Plaque radiotherapy in the management of retinoblastoma. Use as a primary and secondary treatment. Ophthalmology 1993; 100:216-224.
33. Schueler A.O., Fluhs D., Anastassiou G., et al: Beta-ray brachytherapy with (106) Ru plaques for retinoblastoma. Int J RadiatOncolBiol Phys. 2006; 65:1212-1221.
34. Abramson D.H., Schefler A.C.: Transpupillary thermotherapy as initial treatment for small intraocular retinoblastoma: technique and predictors of success. Ophthalmology 2004; 111:984-991.
35. Shields CL, Santos MC, Diniz W et al. Thermotherapy for retinoblastoma.ArchOphthalmol 1999; 117:885-893.
36. Shields J.A., Parsons H., Shields C.L., et al: The role of cryotherapy in the management of retinoblastoma. Am J Ophthalmol 1989; 108:260-264.
37. Singh AD, Shields CL, Shields JA. Prognostic factors in retinoblastoma.JPediatrOphthalmolStrab 2000;37:134-41.
38. Shields CL, Honavar S, Shields JA, Demirci H, Meadows AT. Vitrectomy in eyes with unsuspected retinoblastoma. Ophthalmology. 2000;107: 2250-5.
39. Honavar SG, Shields CL, Shields JA, Demrici H, Naduvilath TJ. Intraocular surgery after treatment of retinoblastoma. Arch Ophthalmol.2001;119: 1613-21.
40. Honavar SG, Reddy VAP, Murthy R, Naik M, Vemuganti GK. Management of orbital retinoblastoma.XI International Congress of Ocular Oncology. Hyderabad, India, 2004.pp.51.
41. Kiran VS, Kannabiran C, ChakravarthiK, Vemuganti GK, Honavar SG. Mutational screening of the RB1gene in Indian patients with retinoblastoma reveals eight novel and several recurrent mutations. Hum Mutat.2003;22:339.
|